Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study

CH Adler, TG Beach, JG Hentz, HA Shill, JN Caviness… - Neurology, 2014 - AAN Enterprises
CH Adler, TG Beach, JG Hentz, HA Shill, JN Caviness, E Driver-Dunckley, MN Sabbagh
Neurology, 2014AAN Enterprises
Objectives: Determine diagnostic accuracy of a clinical diagnosis of Parkinson disease (PD)
using neuropathologic diagnosis as the gold standard. Methods: Data from the Arizona
Study of Aging and Neurodegenerative Disorders were used to determine the predictive
value of a clinical PD diagnosis, using 2 clinical diagnostic confidence levels, PossPD
(never treated or not clearly responsive) and ProbPD (responsive to medications).
Neuropathologic diagnosis was the gold standard. Results: Based on first visit, 9 of 34 (26%) …
Objectives
Determine diagnostic accuracy of a clinical diagnosis of Parkinson disease (PD) using neuropathologic diagnosis as the gold standard.
Methods
Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to determine the predictive value of a clinical PD diagnosis, using 2 clinical diagnostic confidence levels, PossPD (never treated or not clearly responsive) and ProbPD (responsive to medications). Neuropathologic diagnosis was the gold standard.
Results
Based on first visit, 9 of 34 (26%) PossPD cases had neuropathologically confirmed PD while 80 of 97 (82%) ProbPD cases had confirmed PD. PD was confirmed in 8 of 15 (53%) ProbPD cases with <5 years of disease duration and 72 of 82 (88%) with ≥5 years of disease duration. Using final diagnosis at time of death, 91 of 107 (85%) ProbPD cases had confirmed PD. Clinical variables that improved diagnostic accuracy were medication response, motor fluctuations, dyskinesias, and hyposmia.
Conclusions
Using neuropathologic findings of PD as the gold standard, this study establishes the novel findings of only 26% accuracy for a clinical diagnosis of PD in untreated or not clearly responsive subjects, 53% accuracy in early PD responsive to medication (<5 years' duration), and >85% diagnostic accuracy of longer duration, medication-responsive PD. Caution is needed when interpreting clinical studies of PD, especially studies of early disease that do not have autopsy confirmation. The need for a tissue or other diagnostic biomarker is reinforced.
Classification of evidence
This study provides Class II evidence that a clinical diagnosis of PD identifies patients who will have pathologically confirmed PD with a sensitivity of 88% and specificity of 68%.
American Academy of Neurology